Drug-labels.com

Ultiva: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx) NARCOTICS (CDSA I) Current status: Cancelled Post Market
Strength:
1 mg, 2 mg, 5 mg

Patient Medication Information: uses, side effects, how to take - Ultiva

ABOUT THIS MEDICATION

What the medication is used for:

ULTIVA® is a pain medication used before and/ or during surgery.

What it does:

ULTIVA® reduces the pain during surgery.

When it should not be used:

ULTIVA® should not be used in patients who:

  • are allergic to remifentanil
  • are pregnant or nursing

What the medicinal ingredient is:

Remifentanil hydrochloride

What the nonmedicinal ingredients are:

Glycine, hydrochloric acid, water for injection.

WARNINGS AND PRECAUTIONS

BEFORE you undergo surgery, tell your doctor or pharmacist if:

  • you are pregnant or nursing
  • you are allergic to remifentanil

INTERACTIONS WITH THIS MEDICATION

Before taking ULTIVA®, tell your doctor about any other medications that you are using, including:

  • certain antidepressants (selective serotonin reuptake

    inhibitors (SSRI) and serotonin/norepinephrine reuptake inhibitors (SNRI))

  • benzodiazepines (Valium, Versed)
  • opioids (Morphine, Codeine)

They may interact with ULTIVA®.

PROPER USE OF THIS MEDICATION

Usual dose:

The proper dose is determined by a doctor trained in the administration of analgesics and general anesthesia.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Common side effects include: respiratory depression, slow heartbeat, low blood pressure, and skeletal muscle rigidity. Your anesthetist knows how to manage them during surgery.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

You should immediately contact your physician or anesthesia professional if you have any of the following reactions after surgery.

Nausea

Low blood pressure

Vomiting

Muscle tightness

Slow heartbeat

Shivering

Fever

Dizziness

Visual disturbance

Headache

Respiratory depression

Transient cessation of respiration

Itch

Rapid heartbeat

Postoperative pain

High blood pressure

Agitation

Hypoxia

This is not a complete list of side effects. For any unexpected effects while taking ULTIVA®, contact your doctor or pharmacist.

IMPORTANT: PLEASE READ

ULTIVA® Product Monograph Page 30 of 30 REPORTING SUSPECTED SIDE EFFECTS

To monitor drug safety, Health Canada through the Canada Vigilance Program collects information on serious and unexpected effects of drugs. If you suspect you have had a serious or unexpected reaction to this drug you may notify Canada Vigilance:

By toll-free telephone: 866-234-2345

By toll-free fax 866-678-6789

Online: www.healthcanada.gc.ca/medeffect

By email: CanadaVigilance@hc-sc.gc.ca

By regular mail:

Canada Vigilance National Office

Marketed Health Products Safety and Effectiveness Information Division

Marketed Health Products Directorate

Health Products and Food Branch

Health Canada

Tunney’s Pasture, AL 0701C

Ottawa ON K1A 0K9

NOTE: Should you require information related to the management of the side effect, please contact your health care provider before notifying Canada Vigilance. The Canada Vigilance Program does not provide medical advice

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be obtained by contacting the sponsor, AbbVie Corporation at 1-800-699-9948.

Last revised: November 2, 2012

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02230409

Revision date stated in the text: November 2, 2012

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Ultiva

Rx or OTC
Prescription (Rx)?
DIN 02230409, 02230410, 02230411
Schedule(s) NARCOTICS (CDSA I)
Active ingredient(s) Remifentanil (remifentanil hydrochloride)
Dosage form(s) Powder For Solution
Route(s) of administration Intravenous
Drug class (WHO ATC)
  1. N Nervous system drugs
    1. N01 Anesthetics
      1. N01A Anesthetics, general
        1. N01AH Opioid anesthetics
          1. N01AH06 Remifentanil
Company ABBVIE CORPORATION
Current status Cancelled Post Market
Current status date October 2, 2013
Strengths and forms
DIN Strength Dosage form(s) Current status
02230409 1 MG Powder For Solution Cancelled Post Market October 2, 2013
02230410 2 MG Powder For Solution Cancelled Post Market October 2, 2013
02230411 5 MG Powder For Solution Cancelled Post Market October 2, 2013

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.